A Convenient Piece of Junk Science

The EPPC study suggests potential safety issues for mifepristone but employs flawed methodology involving observational data, low statistical power, biased peer review, and reliance on lesser-tier journals. Anti-choice groups dismiss this study as lacking scientific rigor, arguing past decisions based on flawed research led to unnecessary restrictions. The FDA typically expands access to mifepristone unless significant risks are identified, unlike medications like misoprostol with stricter guidelines. Without thorough scientific review or unbiased replication studies, the EPPC findings likely won't sway FDA policy, highlighting the importance of rigorous evidence in regulatory decisions.